Paris-based Ipsen has agreed to acquire Swiss biotech Memo Therapeutics AG in a deal worth more than €700m, adding the clinical-stage BK polyomavirus antibody potravitug to its rare-disease pipeline.
InflaRx is preparing for discussions with regulators in Europe over two drugs that could provide an alternative to patients treated with Amgen’s Tavneos (avacopan), which is set to be removed from the EU market for the rare blood vessel inflammation disease ANCA-associated vasculitis (AAV).
Genmab and AbbVie reported positive phase 3 results for epcoritamab in combination with lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), demonstrating a significant improvement in progression-free survival (PFS) compared with R-GemOx.